Marksrub Ultra Cream is a topical formulation combining Hydroquinone 2% w/w, Mometasone 0.1% w/w, and Tretinoin 0.025% w/w, designed for the management of hyperpigmentation disorders and inflammatory dermatoses. Hydroquinone acts as a depigmenting agent by inhibiting tyrosinase, thereby reducing melanin synthesis and aiding in the treatment of melasma, post-inflammatory hyperpigmentation, and other pigmentary abnormalities. Mometasone, a potent corticosteroid, provides anti-inflammatory, antipruritic, and vasoconstrictive effects, helping to alleviate erythema, swelling, and irritation associated with inflammatory skin conditions. Tretinoin, a retinoid, promotes epidermal cell turnover and collagen synthesis, enhancing skin texture and facilitating the penetration of active ingredients. The synergistic combination of these agents in Marksrub Ultra Cream offers effective management of resistant hyperpigmentation while controlling inflammation and improving overall skin appearance. It is recommended for use under medical supervision due to the potential for corticosteroid-related side effects and tretinoin-induced irritation. Patients should avoid excessive sun exposure and use sunscreen during treatment. Marksrub Ultra Cream is contraindicated in individuals with hypersensitivity to any component and should not be applied to broken or infected skin. Regular follow-up is advised to monitor therapeutic response and adverse effects.